Expertise in
13
conditions

Dr. Jeffrey Giguere

Hematology | Oncology
Greenville Health System
131 Lila Doyle Dr, 
Seneca, SC 
Expertise in
13
conditions
Greenville Health System
131 Lila Doyle Dr, 
Seneca, SC 

Overview

Jeffrey Giguere is a Hematologist and an Oncologist in Seneca, South Carolina. Dr. Giguere is highly rated in 13 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Multiple Myeloma, Vitamin B12 Deficiency, Thrombocytopenia, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 110 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Greenville Health System
131 Lila Doyle Dr, Seneca, SC 29672
Other Locations
Office
300 E McBee Ave, Greenville, SC 29601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

109 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
View 9 Less Clinical Trials

22 Total Publications

Psychometric Properties of the Generalized Anxiety Disorder Scale (GAD-7) in Older Adults With Advanced Cancer.
Psychometric Properties of the Generalized Anxiety Disorder Scale (GAD-7) in Older Adults With Advanced Cancer.
Journal: Psycho-oncology
Published: February 14, 2024
Similar Doctors
Expertise in
49
conditions
Dr. Ross Michels
Hematology | Oncology
Expertise in
49
conditions
Dr. Ross Michels
Hematology | Oncology

Greenville Health System

131 Lila Doyle Dr, 
Seneca, SC 
 (0.1 miles away)
864-888-3717
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ross Michels is a Hematologist and an Oncologist in Seneca, South Carolina. Dr. Michels is highly rated in 49 conditions, according to our data. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Myeloproliferative Neoplasms (MPN), Retroperitoneal Liposarcoma, and Colorectal Cancer.

Expertise in
41
conditions
Dr. James Mcclain
Hematology | Oncology
Expertise in
41
conditions
Dr. James Mcclain
Hematology | Oncology

Anderson Area Cancer Center

2000 E Greenville Street, Suite 5000, 
Anderson, SC 
 (25.2 miles away)
864-512-1658
Languages Spoken:
English
See accepted insurances

James Mcclain is a Hematologist and an Oncologist in Anderson, South Carolina. Dr. Mcclain is highly rated in 41 conditions, according to our data. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Anemia, Colorectal Cancer, and Bone Marrow Aspiration.

Expertise in
30
conditions
Dr. Mark O'rourke
Hematology | Oncology
Expertise in
30
conditions
Dr. Mark O'rourke
Hematology | Oncology

Prisma Health-Upstate

65 International Dr, 
Greenville, SC 
 (39.3 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances

Mark O'rourke is a Hematologist and an Oncologist in Greenville, South Carolina. Dr. O'rourke is highly rated in 30 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Undifferentiated Pleomorphic Sarcoma.

Frequently Asked Questions about Dr. Jeffrey Giguere

How do I make an appointment with Dr. Jeffrey Giguere?

You can book an appointment with Dr. Jeffrey Giguere by calling their office at 864-888-3717. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey Giguere a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey Giguere is classified as an Distinguished expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey Giguere specialize in?

While Dr. Jeffrey Giguere is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Multiple Myeloma, and Vitamin B12 Deficiency. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jeffrey Giguere participate in research or clinical trials?

Yes. Dr. Jeffrey Giguere has published 22 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Jeffrey Giguere's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Giguere's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 46 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile